Topics

Innovent Acquires China Rights to Novel Immunoncology Candidate from Alector

23:09 EDT 26 Mar 2020 | ChinaBio Today

Suzhou Innovent Bio acquired China rights to an anti-SIRP-alpha antibody from Alector, a South San Francisco biotech. AL008 is designed to inhibit the ability of macrophages to interfere with the immune response around tumors. It antagonizes the CD47-SIRP-alpha pathway by degrading the inhibitory receptor on macrophages while engaging Fc gamma to promote immuno-stimulatory pathways, increasing the immune attack on the tumor. In pre-clinical studies, the molecule has shown activity in myeloid and lymphoid cancers. Innovent will lead China development of the molecule and have manufacturing rights. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

Original Article: Innovent Acquires China Rights to Novel Immunoncology Candidate from Alector

NEXT ARTICLE

More From BioPortfolio on "Innovent Acquires China Rights to Novel Immunoncology Candidate from Alector"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...